DiaMedica Therapeutics, Inc. (DMAC) is a leading biopharmaceutical company focused on developing innovative therapies for acute ischemic stroke (AIS) and cardio-renal disease. The company's flagship product candidate, DM199, is being studied in the ReMEDy2 clinical trial, an adaptive design, randomized, double-blind, placebo-controlled trial.

The trial aims to evaluate the efficacy and safety of DM199 in approximately 350 AIS patients at 75 sites across the United States. Patients will receive treatment for three weeks, starting within 24 hours of stroke onset, with a final follow-up at 90 days. ReMEDy2 is specifically targeting the 80% of AIS patients who currently have limited treatment options due to restrictions on existing therapies.

Building on the positive results from DiaMedica's previous ReMEDy1 trial, which demonstrated the safety and potential benefits of DM199, the ReMEDy2 trial has the potential to serve as a pivotal registration study for DM199. DM199 is a synthetic form of human tissue kallikrein-1 (KLK1), a protein that plays a crucial role in regulating blood flow, vasodilation, and mitigating inflammation and oxidative stress. As the first company to develop and clinically study a pharmaceutically active synthetic form of the KLK1 protein, DiaMedica is at the forefront of advancing stroke treatment options.

Clinical trials like ReMEDy2 are essential for advancing medical knowledge and improving patient care. They provide valuable data that regulatory bodies like the FDA use to evaluate the safety and effectiveness of new therapies. DiaMedica's commitment to innovation, rigorous scientific standards, and patient-centric approach make them a trusted leader in the field of acute ischemic stroke research